Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C

Sun Yat-sen University

Status: Not yet enrolling

Conditions: Hepatitis C; Hepatitis B

Treatments: Other: Anti-virus treatment

Study type: Observational

Funder types: Other

Identifiers

NCT05102838

Spark Srudy

Details and patient eligibility

About

Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030. However, at present, the diagnosis rate and treatment rate of chronic HBV and HCV in China are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face.

This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.

Full description

Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. According to the survey, there are about 93 million chronic HBV infected people and 10 million chronic HCV infected people in China, accounting for 36.19% and 14.08% of the global HBV and HCV infected people respectively. Chronic HBV and HCV infection is the main cause of liver cirrhosis and liver cancer, which places a great burden on the national economy.

In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030, including 90% diagnosis rate, 80% treatment rate and 90% cure rate of viral hepatitis, in order to reduce 65% of viral hepatitis related deaths and reduce the disease burden. However, at present, the diagnosis rate of chronic HBV in China is 18.7%, the treatment rate is 10.8%, the diagnosis rate of chronic HCV is 30%, and the treatment rate is 9%, which are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face.

This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.

Enrollment: 60,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• HBsAg/HBV DNA positive
• or anti-HCV/HCV RNA positive

Exclusion criteria

• patients who refused to participate in the study.

Trial design

60,000 participants in 4 patient groups

Hepatitis B cohort

Description:

1. Patients with HBsAg and/or HBV DNA positive; 2. Patients without cirrhosis.

Treatment:

Other: Anti-virus treatment

Hepatitis C cohort

Description:

1. Patients with anti-HCV and/or HCV RNA positive; 2. Patients without cirrhosis.

Treatment:

Other: Anti-virus treatment

Cirrhosis cohort

Description:

1. Patients diagnosised with cirrhosis; 2. Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive.

Treatment:

Other: Anti-virus treatment

Liver cancer cohort

Description:

1. Patients diagnosised with liver cancer; 2. Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive.

Treatment:

Other: Anti-virus treatment